Spots Global Cancer Trial Database for laboratory biomarker analysis
Every month we try and update this database with for laboratory biomarker analysis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | NCT03513562 | Chronic Lymphoc... Ibrutinib Resis... | Ibrutinib Laboratory Biom... Venetoclax | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | NCT01175785 | Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Myelo... | umbilical cord ... fludarabine pho... cyclophosphamid... ex vivo-expande... total-body irra... cyclosporine mycophenolate m... laboratory biom... | 6 Months - 45 Years | Nohla Therapeutics, Inc. | |
| Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia | NCT02689440 | Chronic Phase C... Philadelphia Ch... | Dasatinib Laboratory Biom... Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma | NCT02567435 | Alveolar Rhabdo... Botryoid-Type E... Embryonal Rhabd... Rhabdomyosarcom... Sclerosing Rhab... Spindle Cell Rh... | Cyclophosphamid... Dactinomycin Irinotecan Hydr... Laboratory Biom... Questionnaire A... Radiation Thera... Temsirolimus Vincristine Sul... Vinorelbine | - 40 Years | National Cancer Institute (NCI) | |
| A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) | NCT01824836 | Estrogen Recept... Musculoskeletal... Progesterone Re... Recurrent Breas... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | anastrozole questionnaire a... laboratory biom... pharmacogenomic... | 18 Years - | Eastern Cooperative Oncology Group | |
| Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia | NCT00453388 | Acute Myeloid L... de Novo Myelody... Fanconi Anemia Previously Trea... | Allogeneic Bone... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Nonmyeloablativ... Total-Body Irra... | - | Fred Hutchinson Cancer Center | |
| Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer | NCT02522715 | Castration-Resi... Metastatic Pros... Recurrent Prost... Stage IV Prosta... | Cabazitaxel Enzalutamide Laboratory Biom... Pharmacological... Prednisone | 18 Years - | OHSU Knight Cancer Institute | |
| Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate | NCT00459407 | Adenocarcinoma ... Stage I Prostat... Stage II Prosta... | defined green t... placebo immunohistochem... immunoenzyme te... laboratory biom... biopsy mass spectromet... high performanc... | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib in Treating Patients With Recurrent Glioblastoma | NCT00459381 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | pazopanib hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms in Patients With Cancer | NCT02598726 | Bladder Spasm Malignant Neopl... Pain Urinary Urgency | Curcumin Laboratory Biom... Piperine Extrac... Quality-of-Life... | 18 Years - | Mayo Clinic | |
| Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery | NCT01207726 | Stage IA Non-Sm... Stage IB Non-Sm... | Azacitidine Entinostat Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment | NCT00822458 | Recurrent Child... | vismodegib laboratory biom... pharmacological... | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer | NCT01629498 | Recurrent Lung ... Stage II Non-Sm... Stage IIA Non-S... Stage IIB Non-S... Stage IIIA Non-... Stage IIIB Lung... | Image Guided Ra... Image Guided Ra... Intensity-Modul... Intensity-Modul... Laboratory Biom... Photon Beam Rad... Proton Beam Rad... Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to Therapy | NCT01147029 | Unspecified Adu... | angiogenesis in... laboratory biom... pharmacological... dynamic contras... | 18 Years - | Cancer Research UK | |
| Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia | NCT01024127 | Adult Acute Mye... Childhood Acute... | Laboratory Biom... | - 30 Years | Children's Oncology Group | |
| Sunitinib Malate in Treating Patients With Kidney Cancer | NCT00943839 | Kidney Cancer | sunitinib malat... laboratory biom... pharmacological... | 18 Years - | Centre Antoine Lacassagne | |
| Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci) | NCT00365209 | Healthy, no Evi... Tobacco Use Dis... | laboratory biom... pharmacological... curcumin | 40 Years - | National Cancer Institute (NCI) | |
| Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | NCT02877303 | B Acute Lymphob... B Lymphoblastic... | Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 14 Years - | M.D. Anderson Cancer Center | |
| Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer | NCT01800422 | Stage IA Breast... Stage IB Breast... Stage II Breast... | telapristone ac... placebo therapeutic con... laboratory biom... questionnaire a... | 18 Years - | Northwestern University | |
| Gefitinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer | NCT00033449 | Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... | gefitinib radiation thera... cisplatin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | NCT01153672 | Male Breast Can... Recurrent Breas... Stage IV Breast... | vorinostat laboratory biom... biopsy F-18 16 alpha-f... positron emissi... anastrozole letrozole exemestane gene expression... | 18 Years - | University of Washington | |
| Biomarkers in Patients With Head and Neck Cancer | NCT01466257 | Head and Neck C... | cetuximab cisplatin DNA analysis gene expression... mutation analys... laboratory biom... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT01096342 | Refractory Mult... | dinaciclib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer | NCT02621398 | Stage II Non-Sm... Stage IIIA Non-... Stage IIIB Non-... | 3-Dimensional C... Carboplatin Intensity-Modul... Laboratory Biom... Paclitaxel Pembrolizumab | 18 Years - | Rutgers, The State University of New Jersey | |
| Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy | NCT00897520 | Melanoma (Skin) | recombinant int... proteomic profi... immunoenzyme te... laboratory biom... | - 120 Years | Eastern Cooperative Oncology Group | |
| Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | NCT00075439 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Recurrent Gastr... Recurrent Islet... Somatostatinoma WDHA Syndrome | gefitinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | NCT01120236 | Prostate Adenoc... Recurrent Prost... Stage IV Prosta... | Bicalutamide Cixutumumab Goserelin Aceta... Laboratory Biom... Leuprolide Acet... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer | NCT01220973 | Prostate Cancer | atorvastatin ca... celecoxib laboratory biom... | 18 Years - 120 Years | Rutgers, The State University of New Jersey | |
| Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia | NCT01229956 | Leukemia | DNA methylation... gene expression... microarray anal... reverse transcr... laboratory biom... | 1 Year - 18 Years | Children's Oncology Group | |
| Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery | NCT04955808 | Breast Carcinom... Colon Carcinoma Invasive Carcin... Kidney Carcinom... Liver Carcinoma Malignant Solid... Multiple Myelom... Prostate Carcin... | Biospecimen Col... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | NCT00052520 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... B-cell Adult Ac... B-cell Childhoo... Childhood Chron... Childhood Myelo... Chronic Myelomo... Essential Throm... Polycythemia Ve... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... T-cell Adult Ac... T-cell Childhoo... | therapeutic all... aldesleukin peripheral bloo... allogeneic bone... laboratory biom... gene expression... immunologic tec... flow cytometry polymerase chai... cytogenetic ana... staining method | - | Fred Hutchinson Cancer Center | |
| Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma | NCT01753713 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | dovitinib laboratory biom... | 18 Years - | Case Comprehensive Cancer Center | |
| Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma | NCT01476839 | Recurrent Adult... | basiliximab carmustine etoposide cytarabine melphalan pharmacological... laboratory biom... autologous hema... yttrium Y 90-la... | 18 Years - 70 Years | City of Hope Medical Center | |
| Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer | NCT03103321 | Stage II Prosta... Stage IIA Prost... Stage IIB Prost... Stage III Prost... Stage I Prostat... PSA Level Five ... PSA Level Less ... PSA Level Ten t... | Internet-Based ... Internet-Based ... Best Practice Quality-of-Life... Questionnaire A... Survey Administ... Laboratory Biom... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT01946152 | Multiple Myelom... Recurrent Plasm... Refractory Plas... | Dexamethasone Filgrastim-sndz Laboratory Biom... Pomalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant | NCT02333162 | Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Hemat... | Fludarabine Pho... Melphalan Intensity-Modul... Total Marrow Ir... Allogeneic Hema... Peripheral Bloo... Allogeneic Bone... Tacrolimus Mycophenolate M... Laboratory Biom... | 18 Years - 75 Years | University of Chicago | |
| BMS-247550 in Treating Patients With Stage IV Melanoma | NCT00036764 | Recurrent Melan... Stage IV Melano... | ixabepilone pharmacogenomic... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00482495 | Multiple Myelom... | bevacizumab gene expression... protein express... laboratory biom... | 18 Years - | Mayo Clinic | |
| Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant | NCT02038153 | Acute Myeloid L... Adult Acute Mye... | Laboratory Biom... Lenalidomide | 60 Years - 80 Years | Albert Einstein College of Medicine | |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | NCT01823198 | Accelerated Pha... Acute Erythroid... Acute Megakaryo... Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Blast Phase Chr... Blasts Under 20... Blasts Under 20... Chronic Myelomo... High Risk Myelo... Myelodysplastic... Recurrent Chron... Therapy-Related... Therapy-Related... | Aldesleukin Allogeneic CD56... Allogeneic Hema... Busulfan Fludarabine Pho... Laboratory Biom... Peripheral Bloo... Pharmacological... | 7 Years - 65 Years | M.D. Anderson Cancer Center | |
| Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma | NCT03486197 | Urothelial Carc... | Laboratory Biom... Pembrolizumab Radiation Thera... | 18 Years - | University of Washington | |
| Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | NCT02168270 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma Gliosarcoma | ascorbic acid temozolomide quality-of-life... laboratory biom... | 19 Years - | University of Nebraska | |
| A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | NCT00671788 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Dasatinib Laboratory Biom... | 18 Years - | GOG Foundation | |
| Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas | NCT00042991 | Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... | gefitinib radiation thera... pharmacological... laboratory biom... | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer | NCT00640081 | Colorectal Canc... | cetuximab capecitabine fluorouracil leucovorin calc... oxaliplatin immunohistochem... laboratory biom... | 18 Years - 100 Years | Medical Research Council | |
| Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus | NCT02015559 | Estrogen Recept... HER2-negative B... Oral Complicati... Progesterone Re... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | mucoadhesive or... laboratory biom... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | NCT00939770 | Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Anap... Refractory Mali... Refractory Neur... | Crizotinib Laboratory Biom... Pharmacological... Questionnaire A... | 1 Year - 21 Years | Children's Oncology Group | |
| Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors | NCT00389922 | Unspecified Adu... | lapatinib ditos... vinorelbine dit... comparative gen... cytogenetic ana... gene expression... mutation analys... polymerase chai... polymorphism an... proteomic profi... reverse transcr... immunohistochem... laboratory biom... lapatinib ditos... Vinorelbine dit... | 18 Years - | University of California, Davis | |
| Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma | NCT01979523 | Recurrent Uveal... Stage IV Uveal ... | Laboratory Biom... Pharmacological... Trametinib Uprosertib | 18 Years - | National Cancer Institute (NCI) | |
| Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis | NCT03252600 | Recurrent Prima... | Cyclophosphamid... Dexamethasone Elotuzumab Laboratory Biom... Lenalidomide Pharmacological... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia | NCT05396859 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Decitabine and ... Entrectinib Laboratory Biom... | 18 Years - | OHSU Knight Cancer Institute | |
| Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma | NCT02363283 | Recurrent Uveal... Stage IV Uveal ... | Glembatumumab V... Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Biomarkers in Samples From Young Patients With Neuroblastoma | NCT01358604 | Neuroblastoma | polymerase chai... protein express... western blottin... flow cytometry immunohistochem... laboratory biom... | - 120 Years | Children's Oncology Group | |
| Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery | NCT01473940 | Duct Cell Adeno... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... | ipilimumab gemcitabine hyd... laboratory biom... | 18 Years - | Northwestern University | |
| SU6668 in Treating Patients With Advanced Solid Tumors | NCT00024206 | Unspecified Adu... | orantinib laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | NCT00723099 | Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg... | Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ... | - 69 Years | Fred Hutchinson Cancer Center | |
| Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia | NCT03504644 | B Acute Lymphob... Lymphoblasts 5 ... Recurrent Adult... Recurrent Child... Refractory Acut... T Acute Lymphob... | Laboratory Biom... Venetoclax Vincristine Lip... | 18 Years - | Eastern Cooperative Oncology Group | |
| CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | NCT02757391 | Colorectal Aden... Metastatic Chol... Metastatic Colo... Metastatic Dige... Metastatic Esop... Metastatic Gast... Metastatic Panc... Stage IV Colore... Stage IV Esopha... Stage IV Gastri... Stage IV Pancre... Stage IVA Color... Stage IVB Color... | Adoptive Immuno... Aldesleukin Cyclophosphamid... Laboratory Biom... Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | NCT00063999 | Recurrent Uteri... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IVA Uteri... Stage IVB Uteri... | Carboplatin Cisplatin Doxorubicin Hyd... Filgrastim Laboratory Biom... Paclitaxel Pegfilgrastim Quality-of-Life... | 18 Years - | GOG Foundation | |
| Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma | NCT03296371 | Alveolar Rhabdo... Embryonal Rhabd... | Biospecimen Col... Laboratory Biom... Questionnaire A... | - 50 Years | Children's Oncology Group | |
| Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission | NCT00268528 | Childhood Acute... | Compliance Moni... Laboratory Biom... Mercaptopurine Methotrexate Questionnaire A... Study of Socioe... | - 21 Years | Children's Oncology Group | |
| Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer | NCT00967889 | Prostate Cancer | gene expression... protein analysi... biologic sample... laboratory biom... | - | National Cancer Institute (NCI) | |
| Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery | NCT01206140 | Recurrent Adult... Stage III Adult... Stage IV Adult ... | Laboratory Biom... Selumetinib Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic | NCT00003440 | HER2-negative B... HER2-positive B... Recurrent Breas... Stage IIIC Brea... Stage IV Breast... | paclitaxel trastuzumab quality-of-life... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS | NCT01300572 | Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute... | Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An... | 18 Years - | Fred Hutchinson Cancer Center | |
| Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery | NCT01537107 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IV Pancre... Unspecified Adu... | vismodegib sirolimus positron emissi... computed tomogr... pharmacological... laboratory biom... fludeoxyglucose... | 18 Years - | Mayo Clinic | |
| Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery | NCT00025246 | Gastrointestina... | imatinib mesyla... laboratory biom... | 16 Years - | National Cancer Institute (NCI) | |
| Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer | NCT00601406 | Breast Cancer Cervical Cancer Endometrial Can... Fallopian Tube ... Ovarian Cancer Primary Periton... Prostate Cancer Sarcoma Vaginal Cancer Vulvar Cancer | gene expression... gene rearrangem... polymorphism an... laboratory biom... radiation thera... | - | National Cancer Institute (NCI) | |
| ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00770471 | Brain and Centr... | temozolomide veliparib DNA methylation... gene expression... mutation analys... proteomic profi... high performanc... immunoenzyme te... laboratory biom... mass spectromet... pharmacogenomic... pharmacological... adjuvant therap... radiation thera... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02299518 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Secondary Acute... | mitoxantrone hy... etoposide cytarabine selinexor laboratory biom... pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer | NCT02581943 | Recurrent Non-S... Stage IIIB Non-... Stage IV Non-Sm... | Carboplatin Laboratory Biom... Paclitaxel Pembrolizumab Quality-of-Life... | 18 Years - | Wake Forest University Health Sciences | |
| Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | NCT02966587 | Castration Leve... Hormone-Resista... Microsatellite ... | Durvalumab Laboratory Biom... | 18 Years - | University of Washington | |
| Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer | NCT00118040 | Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd... | Genistein Laboratory Biom... Pharmacological... Placebo Adminis... Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) | |
| Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma | NCT00514085 | Melanoma (Skin) | recombinant hum... immunohistochem... laboratory biom... pharmacological... | 18 Years - | Canadian Cancer Trials Group | |
| GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer | NCT01918306 | Estrogen Recept... Human Epidermal... Triple Negative... Recurrent Breas... Stage IV Breast... Triple-negative... | cisplatin laboratory biom... pharmacological... dynamic contras... GDC -0941 | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT01527149 | Stage I Mantle ... Stage II Contig... Stage II Non-Co... Stage III Mantl... Stage IV Mantle... | Autologous Hema... Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Laboratory Biom... Methotrexate Ofatumumab Vincristine Sul... | 18 Years - 70 Years | Roswell Park Cancer Institute | |
| Diindolylmethane in Preventing Cancer in Healthy Volunteers | NCT00784394 | Healthy, no Evi... | diindolylmethan... placebo pharmacological... laboratory biom... quality-of-life... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | NCT02178436 | Acinar Cell Ade... Duct Cell Adeno... Stage IV Pancre... | gemcitabine hyd... Selinexor Pharmacological... Laboratory Biom... Nab paclitaxel | 19 Years - | Barbara Ann Karmanos Cancer Institute | |
| Depression and Interleukin-6 Production in Patients With Ovarian Epithelial Cancer | NCT00460200 | Depression Fatigue Ovarian Cancer Psychosocial Ef... Sleep Disorders | polymorphism an... laboratory biom... physiologic tes... questionnaire a... conventional su... fatigue assessm... psychosocial as... | 18 Years - 55 Years | Jonsson Comprehensive Cancer Center | |
| Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer | NCT01058785 | Lung Neoplasm Carcinoma, Bron... | Lucanix | 18 Years - | NovaRx Corporation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
